- Conditions
- Advanced Solid Tumor
- Interventions
- ONC-783
- Drug
- Lead sponsor
- OncoC4, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2028
- U.S. locations
- 3
- States / cities
- New York, New York • Philadelphia, Pennsylvania • Houston, Texas
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1–24
of 2,082
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Localized Resectable Neuroblastoma, Localized Unresectable Neuroblastoma, Regional Neuroblastoma, Stage 4 Neuroblastoma, Stage 4S Neuroblastoma
- Interventions
- Clinical Observation, Cyclophosphamide, Laboratory Biomarker Analysis, Magnetic Resonance Imaging, Prednisone, Therapeutic Immune Globulin
- Other · Drug · Procedure + 1 more
- Lead sponsor
- Children's Oncology Group
- Network
- Eligibility
- Up to 8 Years
- Enrollment
- 53 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2004 – 2022
- U.S. locations
- 97
- States / cities
- Birmingham, Alabama • Tucson, Arizona • Little Rock, Arkansas + 78 more
- Conditions
- Fallopian Tube Carcinoma, Primary Peritoneal Carcinoma, Recurrent Ovarian Carcinoma
- Interventions
- Laboratory Biomarker Analysis, PEG-PEI-cholesterol Lipopolymer-encased IL-12 DNA Plasmid Vector GEN-1
- Other · Biological
- Lead sponsor
- Gynecologic Oncology Group
- Network
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 22 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2016
- U.S. locations
- 11
- States / cities
- Birmingham, Alabama • Phoenix, Arizona • Aurora, Colorado + 8 more
- Conditions
- Ischemic Heart Disease (IHD), Cardiac Magnetic Resonance Imaging, Myocardial Blood Flow
- Interventions
- Quantitative Myocardial Blood Flow Evaluation, Qualitative Myocardial Blood Flow Evaluation, Gadavist, Vasodilator, Blood draw for the laboratory assessment
- Diagnostic Test · Drug
- Lead sponsor
- Brigham and Women's Hospital
- Other
- Eligibility
- 35 Years to 85 Years
- Enrollment
- 1,000 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2029
- U.S. locations
- 13
- States / cities
- San Francisco, California • Louisville, Kentucky • Boston, Massachusetts + 9 more
- Conditions
- Adult Rhabdomyosarcoma, Childhood Alveolar Rhabdomyosarcoma, Childhood Embryonal Rhabdomyosarcoma, Metastatic Childhood Soft Tissue Sarcoma, Stage IV Adult Soft Tissue Sarcoma, Untreated Childhood Rhabdomyosarcoma
- Interventions
- Cixutumumab, Cyclophosphamide, Dactinomycin, Doxorubicin Hydrochloride, Etoposide, Ifosfamide, Irinotecan Hydrochloride, Laboratory Biomarker Analysis, Temozolomide, Vincristine Sulfate Liposome
- Biological · Drug · Other
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- Up to 49 Years
- Enrollment
- 175 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2016
- U.S. locations
- 121
- States / cities
- Birmingham, Alabama • Phoenix, Arizona • Little Rock, Arkansas + 100 more
- Conditions
- Depressive Symptoms, Fatigue, Psychosocial Effects of Cancer and Its Treatment, Stage IIA Colon Cancer, Stage IIA Rectal Cancer, Stage IIB Colon Cancer, Stage IIB Rectal Cancer, Stage IIC Colon Cancer, Stage IIC Rectal Cancer, Stage IIIA Colon Cancer, Stage IIIA Rectal Cancer, Stage IIIB Colon Cancer, Stage IIIB Rectal Cancer, Stage IIIC Colon Cancer, Stage IIIC Rectal Cancer, Stage IVA Colon Cancer, Stage IVA Rectal Cancer, Stage IVB Colon Cancer, Stage IVB Rectal Cancer
- Interventions
- Yoga Skills Training (YST), questionnaire administration, fatigue and depressive symptom assessment and management, psychological stress assessment, laboratory biomarker analysis, Attention Control
- Behavioral · Other
- Lead sponsor
- Vanderbilt-Ingram Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 3 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2015
- U.S. locations
- 1
- States / cities
- Nashville, Tennessee
- Conditions
- Mild Cognitive Impairment (MCI), Opioid Use, Cognitive Dysfunction, Postoperative Pain
- Interventions
- Not listed
- Lead sponsor
- Miklos Kertai
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 552 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2027 – 2032
- U.S. locations
- 1
- States / cities
- Nashville, Tennessee
- Conditions
- Lung Cancer, Metastatic Cancer
- Interventions
- erlotinib hydrochloride, immunoenzyme technique, laboratory biomarker analysis, liquid chromatography, mass spectrometry, pharmacological study, stereotactic radiosurgery
- Drug · Other · Radiation
- Lead sponsor
- University of California, San Francisco
- Other
- Eligibility
- 18 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009
- U.S. locations
- 1
- States / cities
- San Francisco, California
- Conditions
- Relapse Remitting Multiple Sclerosis
- Interventions
- Ofatumumab
- Drug
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 18 Years to 35 Years
- Enrollment
- 180 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2022 – 2026
- U.S. locations
- 35
- States / cities
- Chandler, Arizona • Phoenix, Arizona • Los Angeles, California + 31 more
- Conditions
- Type 2 Diabetes
- Interventions
- Biophoton Generators
- Device
- Lead sponsor
- First Institute of All Medicines
- Other
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 46 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2027
- U.S. locations
- 2
- States / cities
- Tampa, Florida • Butler, Pennsylvania
- Conditions
- Non-small Cell Lung Cancer (NSCLC)
- Interventions
- ROSE (presence of cytotech) & liquid prep, NO-ROSE (absence of cytotech) & liquid prep, ROSE (presence of cytotech) & tissue clot sample, NO-ROSE (absence of cytotech) & tissue clot sample
- Other
- Lead sponsor
- Johns Hopkins University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 349 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2026
- U.S. locations
- 4
- States / cities
- Chicago, Illinois • Baltimore, Maryland • Charleston, South Carolina
- Conditions
- Grade 2 Meningioma, Intracranial Meningioma
- Interventions
- Biospecimen Collection, Clinical Observation, Intensity-Modulated Radiation Therapy, Laboratory Biomarker Analysis, Magnetic Resonance Imaging, Proton Beam Radiation Therapy, Quality-of-Life Assessment
- Procedure · Other · Radiation
- Lead sponsor
- NRG Oncology
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 162 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2032
- U.S. locations
- 198
- States / cities
- Birmingham, Alabama • Phoenix, Arizona • Scottsdale, Arizona + 162 more
- Conditions
- Bladder Cancer
- Interventions
- Registry
- Other
- Lead sponsor
- University of Kansas Medical Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 1,000 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2035
- U.S. locations
- 1
- States / cities
- Kansas City, Kansas
- Conditions
- Anxiety Disorder, Breast Cancer, Depression, Psychosocial Effects of Cancer and Its Treatment
- Interventions
- laboratory biomarker analysis, questionnaire administration, study of socioeconomic and demographic variables, assessment of therapy complications, psychosocial assessment and care, therapeutic conventional surgery
- Other · Procedure
- Lead sponsor
- Wake Forest University Health Sciences
- Other
- Eligibility
- 18 Years to 120 Years · Female only
- Enrollment
- 24 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2010
- U.S. locations
- 1
- States / cities
- Winston-Salem, North Carolina
- Conditions
- Breast Cancer Screening
- Interventions
- Schirmer Strip
- Diagnostic Test
- Lead sponsor
- Namida Lab
- Industry
- Eligibility
- 18 Years to 100 Years · Female only
- Enrollment
- 1,500 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2024
- U.S. locations
- 1
- States / cities
- Fayetteville, Arkansas
- Conditions
- Open Burn Pit Exposure
- Interventions
- Health survey for physical and mental health comorbidities, epigenetic marker and heavy metals in blood and urine samples
- Diagnostic Test
- Lead sponsor
- Central Arkansas Veterans Healthcare System
- Federal
- Eligibility
- 25 Years to 70 Years
- Enrollment
- 330 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2023 – 2027
- U.S. locations
- 1
- States / cities
- North Little Rock, Arkansas
- Conditions
- Advanced Lymphoma, Advanced Malignant Solid Neoplasm, Bladder Carcinoma, Breast Carcinoma, Cervical Carcinoma, Colon Carcinoma, Colorectal Carcinoma, Endometrial Carcinoma, Esophageal Carcinoma, Exocrine Pancreas Carcinoma, Gastric Carcinoma, Glioma, Head and Neck Carcinoma, Hematopoietic and Lymphoid Cell Neoplasm, Kidney Carcinoma, Liver Carcinoma, Lung Carcinoma, Lymphoma, Malignant Uterine Corpus Neoplasm, Malignant Uterine Neoplasm, Melanoma, Multiple Myeloma, Ovarian Carcinoma, Prostate Carcinoma, Rectal Carcinoma, Recurrent Bladder Carcinoma, Recurrent Breast Carcinoma, Recurrent Cervical Carcinoma, Recurrent Colon Carcinoma, Recurrent Colorectal Carcinoma, Recurrent Esophageal Carcinoma, Recurrent Gastric Carcinoma, Recurrent Glioma, Recurrent Head and Neck Carcinoma, Recurrent Liver Carcinoma, Recurrent Lung Carcinoma, Recurrent Lymphoma, Recurrent Malignant Solid Neoplasm, Recurrent Malignant Uterine Corpus Neoplasm, Recurrent Melanoma, Recurrent Multiple Myeloma, Recurrent Ovarian Carcinoma, Recurrent Pancreatic Carcinoma, Recurrent Prostate Carcinoma, Recurrent Rectal Carcinoma, Recurrent Skin Carcinoma, Recurrent Thyroid Gland Carcinoma, Refractory Lymphoma, Refractory Malignant Solid Neoplasm, Refractory Multiple Myeloma, Skin Carcinoma, Thyroid Gland Carcinoma
- Interventions
- Adavosertib, Afatinib, Afatinib Dimaleate, Binimetinib, Biopsy Procedure, Biospecimen Collection, Capivasertib, Computed Tomography, Copanlisib, Copanlisib Hydrochloride, Crizotinib, Cytology Specimen Collection Procedure, Dabrafenib, Dabrafenib Mesylate, Dasatinib, Defactinib, Defactinib Hydrochloride, Echocardiography Test, Erdafitinib, Fexagratinib, Ipatasertib, Laboratory Biomarker Analysis, Larotrectinib, Larotrectinib Sulfate, Magnetic Resonance Imaging, Multigated Acquisition Scan, Nivolumab, Osimertinib, Palbociclib, Pertuzumab, PI3K-beta Inhibitor GSK2636771, Radiologic Examination, Radionuclide Imaging, Relatlimab, Sapanisertib, Sunitinib Malate, Taselisib, Trametinib, Trastuzumab, Trastuzumab Emtansine, Ulixertinib, Vismodegib
- Drug · Procedure · Other + 1 more
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 6,452 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2027
- U.S. locations
- 1405
- States / cities
- Birmingham, Alabama • Fairhope, Alabama • Mobile, Alabama + 847 more
- Conditions
- Non-small Cell Lung Cancer
- Interventions
- Cisplatin, Carboplatin, Pemetrexed, Pembrolizumab, Abraxane, Paclitaxel
- Drug
- Lead sponsor
- H. Lee Moffitt Cancer Center and Research Institute
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 318 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2030
- U.S. locations
- 11
- States / cities
- Tampa, Florida • Baton Rouge, Louisiana • Baltimore, Maryland + 5 more
- Conditions
- Arrhythmia, Cardiovascular Diseases, Heart Failure, CVD
- Interventions
- Not listed
- Lead sponsor
- CardioDx
- Industry
- Eligibility
- 18 Years to 90 Years
- Enrollment
- 1,564 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2011
- U.S. locations
- 8
- States / cities
- Anchorage, Alaska • Palo Alto, California • Minneapolis, Minnesota + 5 more
- Conditions
- Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
- Interventions
- Acalabrutinib, Laboratory Biomarker Analysis, Obinutuzumab, Patient Observation, Quality-of-Life Assessment
- Drug · Other · Biological
- Lead sponsor
- Mayo Clinic
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 120 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2036
- U.S. locations
- 3
- States / cities
- Scottsdale, Arizona • Jacksonville, Florida • Rochester, Minnesota
- Conditions
- Rheumatoid Arthritis
- Interventions
- tofacitinib 5mg po bid
- Drug
- Lead sponsor
- University of California, Los Angeles
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 37 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2017
- U.S. locations
- 1
- States / cities
- Los Angeles, California
- Conditions
- Accelerated Phase Chronic Myelogenous Leukemia, Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Chronic Phase Chronic Myelogenous Leukemia, Relapsing Chronic Myelogenous Leukemia
- Interventions
- dasatinib, diagnostic laboratory biomarker analysis, pharmacological study, cyclosporine
- Drug · Other
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 4 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2011
- U.S. locations
- 2
- States / cities
- Aurora, Colorado • Denver, Colorado
- Conditions
- Diabetes, Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2, Healthy
- Interventions
- No treatment given
- Other
- Lead sponsor
- Novo Nordisk A/S
- Industry
- Eligibility
- 14 Years to 40 Years
- Enrollment
- 61 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2013 – 2015
- U.S. locations
- 1
- States / cities
- Princeton, New Jersey
- Conditions
- Parkinson Disease, Parkinsons Disease With Dementia
- Interventions
- Placebo Oral Capsule, Nilotinib 150mg oral capsule [Tasigna], Nilotinib 300mg oral capsule [Tasigna]
- Drug
- Lead sponsor
- Georgetown University
- Other
- Eligibility
- 40 Years to 90 Years
- Enrollment
- 75 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2020
- U.S. locations
- 1
- States / cities
- Washington D.C., District of Columbia